← Leaderboards
John K Neubert
University Of Florida
$3,553,315
Attributed
$6,171,778
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,647,793 · 7
By mechanism
U54$3,476,015 · 1
R01$3,467,536 · 1
R44$1,148,589 · 1
R21$818,024 · 2
K22$540,000 · 1
R43$197,629 · 1
Top collaborators
- Robert M Caudle9 shared
- Richard H Mills3 shared
- Niall P Murphy2 shared
- Alejandro Jose Almarza1 shared
- Yenisel Cruz-Almeida1 shared
- Michael S Gold1 shared
- Richard Ohrbach1 shared
- Sonia Sharma1 shared
Most similar at University Of Florida
Same institution · by research overlap
- Robert M Caudle$7,021,665
- Margarete C Ribeiro-Dasilva$1,444,940
- Yenisel Cruz-Almeida$13,117,222
- Joseph L Riley$6,470,686
- Paul R Carney$38,125
Others in their field
Top investigators on “Analgesics”
- Richard T D'aquila · Massachusetts General Hospital$27,454,413
- Yasmin L Hurd · Icahn School Of Medicine At Mount Sinai$25,078,909
- David J Julius · University Of California, San Francisco$24,283,903
- Sandra D. Comer · New York State Psychiatric Institute$21,433,459
- Lynn Kirkpatrick · Ensysce Biosciences, Inc.$20,649,999
- Maurizio Fava · Massachusetts General Hospital$19,316,294
Research focus
AnalgesicsPainRewardsAbsence Of Pain SensationBehavioralChronic PainAnimalsPharmaceutical PreparationsSocietiesCostRodentBehavioral AssayProgramsInnovationResponseAffectBehaviorPain MeasurementOpioidFutureRattusFoundationsCannabinoidsBehavior Assessment
Grant awards (21)
Collaborative for REsearch to AdvanceTMD Evidence (CREATE)$3,476,015
U54 · FY2025 · DE
Opioid and cannabinoid interactions in pain and reward$615,440
R01 · FY2024 · DA
Opioid and cannabinoid interactions in pain and reward$100,000
R01 · FY2024 · DA · contact PI
Opioid and cannabinoid interactions in pain and reward$615,440
R01 · FY2023 · DA · contact PI
Kinetics and target engagement for a Phase II trial of RTX for cancer pain$100,000
R01 · FY2023 · DA · contact PI
Opioid and cannabinoid interactions in pain and reward$615,440
R01 · FY2022 · DA · contact PI
Opioid and cannabinoid interactions in pain and reward$95,168
R01 · FY2022 · DA · contact PI
Opioid and cannabinoid interactions in pain and reward$615,440
R01 · FY2021 · DA · contact PI
Opioid and cannabinoid interactions in pain and reward$95,168
R01 · FY2021 · DA · contact PI
Opioid and cannabinoid interactions in pain and reward$615,440
R01 · FY2020 · DA · contact PI
Operant Behavioral Instrument for Measuring Trigeminal Neuropathic Pain in Rodent$569,718
R44 · FY2011 · DA
Operant Behavioral Instrument for Measuring Trigeminal Neuropathic Pain in Rodent$578,871
R44 · FY2010 · DA
Placebos as insights into intersections of pain and reward in a preclinical model$191,457
R21 · FY2010 · DA · contact PI
Placebos as insights into intersections of pain and reward in a preclinical model$231,716
R21 · FY2009 · DA · contact PI
Operant Behavioral Instrument for Measuring Pain in Rodents$197,629
R43 · FY2008 · DA
Novel Operant Thermal Assessments of Orofacial Pain$176,601
R21 · FY2007 · DE · contact PI
Novel Operant Thermal Assessments of Orofacial Pain$218,250
R21 · FY2006 · DE · contact PI
Molecular Targeting of the Vanilloid-1 Receptor$135,000
K22 · FY2006 · DE · contact PI
Molecular Targeting of the Vanilloid-1 Receptor$135,000
K22 · FY2005 · DE
Molecular Targeting of the Vanilloid-1 Receptor$135,000
K22 · FY2004 · DE
Molecular Targeting of the Vanilloid-1 Receptor$135,000
K22 · FY2003 · DE